Edition:
India

Mirati Therapeutics Inc (MRTX.OQ)

MRTX.OQ on NASDAQ Stock Exchange Capital Market

17.05USD
21 Nov 2017
Change (% chg)

$-1.20 (-6.58%)
Prev Close
$18.25
Open
$18.60
Day's High
$19.00
Day's Low
$16.90
Volume
129,471
Avg. Vol
167,064
52-wk High
$19.10
52-wk Low
$2.70

Latest Key Developments (Source: Significant Developments)

Mirati prices public offering of 2 mln shares at $13 per share​
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Mirati Therapeutics Inc -:Mirati Therapeutics announces pricing of public offering of common stock.Mirati Therapeutics Inc - ‍pricing of underwritten public offering of 2 million shares of its common stock at a price to public of $13.00 per share​.  Full Article

Mirati announces advancement of opportunities with inhibitor programs
Tuesday, 14 Nov 2017 

Nov 13 (Reuters) - Mirati Therapeutics Inc ::Mirati Therapeutics announces advancement of first-in-class opportunities with sitravatinib and kras inhibitor programs.Mirati Therapeutics - ‍"reprioritizing" development programs to capitalize on data and development opportunities in its sitravatinib and kras programs​.Mirati Therapeutics - ‍reallocation of resources to support expansion of sitravatinib and kras programs, is expected to fund operations into late 2019​.  Full Article

Mirati Therapeutics reports Q3 loss per share of $0.65
Thursday, 2 Nov 2017 

Nov 1 (Reuters) - Mirati Therapeutics Inc :Mirati Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.65.Q3 earnings per share view $-0.82 -- Thomson Reuters I/B/E/S.‍Research and development expenses for Q3 of 2017 were $13.5 million, compared to $16.1 million for same period in 2016​.  Full Article

Mirati Therapeutics' says drug included in Stand Up To Cancer's clinical trial initiative for NSCLC patients
Friday, 13 Oct 2017 

Oct 12 (Reuters) - Mirati Therapeutics Inc :Mirati Therapeutics' mocetinostat included in stand up to cancer's cutting-edge clinical trial initiative for NSCLC patients.  Full Article

Broadfin Capital, LLC reports 5.02 pct passive stake in Mirati Therapeutics
Thursday, 11 Aug 2016 

Mirati Therapeutics Inc : Broadfin Capital, LLC reports 5.02 pct passive stake in Mirati Therapeutics as of August 8, 2016 - SEC Filing Source - http://bit.ly/2aMdcIv Further company coverage: [MRTX.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Mirati Therapeutics reports Q2 loss per share of $1.11
Friday, 5 Aug 2016 

Mirati Therapeutics Inc : Q2 loss per share $1.11 . Mirati therapeutics reports financial results and provides business update for the second quarter 2016 .Q2 earnings per share view $-1.15 -- Thomson Reuters I/B/E/S.  Full Article

Mirati Therapeutics, Inc announces leadership changes
Wednesday, 23 Mar 2016 

Mirati Therapeutics, Inc:Says promotion of Jamie A. Donadio to Senior Vice President and Chief Financial Officer, effective as of March 21, 2016.  Full Article

Mirati Therapeutics Inc Initiates Glesatinib (MGCD265) Phase 2 Trial In Non-Small Cell Lung Cancer (NSCLC)
Monday, 21 Dec 2015 

Mirati Therapeutics Inc:Announced that the Phase 2 clinical trial of glesatinib (MGCD265) has commenced.Also announced that "glesatinib" is the proposed generic name for MGCD265.  Full Article

BRIEF-Mirati announces advancement of opportunities with inhibitor programs

* Mirati Therapeutics announces advancement of first-in-class opportunities with sitravatinib and kras inhibitor programs